Saxsons Group — India's trusted nuclear medicine, radiotherapy, oncosurgery, dosimetry and cyclotron supplier since 1986
Peer-ReviewedPubMedResearch ArticleAnnals of nuclear medicine · 2026

Quantitative Imaging Evaluation of Structural and Densitometric Changes in Major Salivary Glands After 177Lu PSMA Radioligand Therapy.

Köylüce N, Demir F.

Abstract

ObjectiveProstate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) provides a survival advantage in metastatic castration-resistant prostate cancer (mCRPC). However, the physiologically high PSMA-ligand uptake in salivary glands makes these organs susceptible to radiation damage. The aim of this study is to examine the changes occurring in salivary glands after PSMA-RLT and to evaluate their relationship with treatment-related parameters, including cumulative administered activity and number of RLT cycles.MethodThe study included 68 mCRPC patients who received 177Lu PSMA-617 treatment. Volume, surface area, density, and PSMA uptake levels were calculated for the parotid and submandibular glands in pre- and post-treatment imaging. Treatment-related changes and their associations with baseline imaging parameters, treatment timing, cumulative administered activity, and number of RLT cycles were statistically analyzed.FindingsAfter RLT, parotid glands showed significant decreases in SUVmean, volume, surface area, and PSMA total activity (all p ConclusionPSMA-targeted RLT was associated with significant imaging-detectable structural alterations and reductions in PET-derived glandular activity in the major salivary glands. CT-derived density significantly decreased in the submandibular glands, whereas parotid density remained stable. No baseline imaging-, BMI-, time-, or administered activity-related parameter remained significantly associated with post-treatment glandular changes after correction for multiple testing.

Identifiers

Radar topics

Related in the same topic

The oncologist · 2026
An Assessment of Time Toxicity in Patients Receiving [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
European journal of nuclear medicine and molecular imaging · 2026
Tolerability of [<sup>161</sup>Tb]Tb-SibuDAB in comparison to other PSMA-targeting radioligands in the preclinical setting.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
Prognostic Value of [<sup>18</sup>F]FDG PET Combined with [<sup>68</sup>Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [<sup>177</sup>Lu]Lu-PSMA-617.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
Clinical Trial Protocol for LPS-Boost: Intensified [<sup>177</sup>Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [<sup>177</sup>Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer.
International urology and nephrology · 2026
Efficacy, safety, and quality of life outcomes of [&lt;sup&gt;177&lt;/sup&gt;Lu] Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: a GRADE-assessed systematic review, meta-analysis and trial sequential analysis.